Similar Papers

Paper Title
Journal
Date
Author
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer
Floor J Backes ... David O'Malley
Gynecologic Oncology | VOL. 162
Floor J Backes, et. al.Floor J Backes ... David O'Malley
14 Jul 2021
Abstract C47: Association of folate receptor alpha (FRα) expression level and clinical activity of IMGN853 (mirvetuximab soravtansine), a FRα-targeting antibody-drug conjugate (ADC), in FRα -expressing platinum-resistant epithelial ovarian cancer (EOC) patients (pts)
Lainie P Martin ... Michael Birrer
Molecular Cancer Therapeutics | VOL. 14
Lainie P Martin, et. al.Lainie P Martin ... Michael Birrer
01 Dec 2015
Folate receptor alpha expression is widely observed in uterine and ovarian carcinosarcoma (209)
Ayumi Saito ... Kan Yonemori
Gynecologic Oncology | VOL. 166
Ayumi Saito, et. al.Ayumi Saito ... Kan Yonemori
01 Aug 2022
Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications
Sam Lawn ... Kurt Stahl
Cancer Research | VOL. 84
Sam Lawn, et. al.Sam Lawn ... Kurt Stahl
22 Mar 2024
View more papers

More From: Gynecologic Oncology

Paper Title
Journal
Date
Author
Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
Andrea Neilson ... Jessica N Mcalpine
Gynecologic oncology | VOL. 193
Andrea Neilson, et. al.Andrea Neilson ... Jessica N Mcalpine
01 Feb 2025
What happens after menopause? (WHAM): A prospective controlled study of cognition 24months after premenopausal risk-reducing salpingo-oophorectomy.
Pauline M Maki ... Martha Hickey
Gynecologic oncology | VOL. 193
Pauline M Maki, et. al.Pauline M Maki ... Martha Hickey
01 Feb 2025
Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups
Franziska Siegenthaler ... Michael D Mueller
Gynecologic Oncology | VOL. 193
Franziska Siegenthaler, et. al.Franziska Siegenthaler ... Michael D Mueller
01 Feb 2025
Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2 mutations
S Gordhandas ... E Aviki
Gynecologic Oncology | VOL. 193
S Gordhandas, et. al.S Gordhandas ... E Aviki
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.